Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

9.075 -0.105 (-1.14%)
Delayed Quote Updated: 11:01 AM EST, Nov 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
News headline image
Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
Compass Pathways (NASDAQ:CMPS) Shares Plunge 42% After Q2 Report Despite Narrower-Than-Expected Loss ↗
Via Chartmill
News headline image
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
Issued on behalf of Helus Pharma (Nasdaq: HELP) 
From USA News Group
Via GlobeNewswire
News headline image
Compass Pathways Q2 Earnings Call Highlights ↗
Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its new drug application, or NDA, filing for COMP360 in treatment-resistant depression in the fourth quarter of 2026, following... 
Via MarketBeat
Topics Cannabis Earnings Government
News headline image
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet. ↗
Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market. 
Via The Motley Fool
Topics ETFs Government
News headline image
Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know. ↗
Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline. 
Via The Motley Fool
News headline image
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up ↗
Compass Pathways (NASDAQ:CMPS) said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Elects Kathleen Tregoning to Board of Directors
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins ↗
Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass (CMPS) Q1 2026 Earnings Transcript ↗
Compass (CMPS) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Compass Pathways Q1 Earnings Call Highlights ↗
Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for... 
Via MarketBeat
Topics Cannabis Earnings Government
News headline image
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
These 3 Psychedelic Stocks Activated After Trump's Executive Order ↗
Via MarketBeat
Topics Government
News headline image
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher
From Compass Pathfinder Limited
Via Business Wire
News headline image
Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About ↗
Compass Pathways is already in the final stage of development on a psychedelic medicine to treat depression. 
Via The Motley Fool
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.